|
C2ORF47 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66777702759191E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.4669155607171E-13 |
| Normal-vs-Stage2 |
8.631700E-04 |
| Normal-vs-Stage3 |
7.18869408444789E-13 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.580600E-01 |
| Stage1-vs-Stage3 |
1.792350E-01 |
| Stage1-vs-Stage4 |
4.607200E-04 |
| Stage2-vs-Stage3 |
4.512300E-02 |
| Stage2-vs-Stage4 |
6.629800E-04 |
| Stage3-vs-Stage4 |
2.776400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.33146835171283E-14 |
| Normal-vs-AfricanAmerican |
8.41790000039033E-07 |
| Normal-vs-Asian |
1.02499997378658E-09 |
| Caucasian-vs-AfricanAmerican |
8.322200E-01 |
| Caucasian-vs-Asian |
7.045400E-01 |
| AfricanAmerican-vs-Asian |
9.471600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.04702921280386E-12 |
| Normal-vs-Female |
1.66122671174662E-12 |
| Male-vs-Female |
6.353400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.01794136955868E-12 |
| Normal-vs-Age(41-60Yrs) |
3.92463839204993E-13 |
| Normal-vs-Age(61-80Yrs) |
5.21099829953187E-11 |
| Normal-vs-Age(81-100Yrs) |
9.624000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.979400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.898000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.640400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.764000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.369000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.318000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.079000E-01 |
| Classical-VS-Follicular |
2.443200E-01 |
| Classical-VS-Other |
8.674600E-01 |
| Classical-VS-Normal |
1.63125069008174E-12 |
| Tall-VS-Follicular |
2.065200E-01 |
| Tall-VS-Other |
9.969200E-01 |
| Tall-VS-Normal |
4.86920004316715E-09 |
| Follicular-VS-Other |
5.811800E-01 |
| Follicular-VS-Normal |
9.43150000320969E-08 |
| Other-VS-Normal |
5.703800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.55901982832074E-12 |
| Normal-vs-N1 |
2.99760216648792E-15 |
| N0-vs-N1 |
4.236100E-04 |
|
|
